Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 3/20 | 0.44 |
| ▸ | GPR6 | P46095 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750533 | 0.87 | TYK2 (0.53) | TYK2GPR6FGFR1SRCEGFR | |
| SCHEMBL5747419 | 0.83 | CYP11B1 (0.38) | GPR6KDRROCK2 | |
| SCHEMBL5750876 | 0.80 | ALDH1A1 (0.38) | FGFR1SRCKDRROCK2 | |
| SCHEMBL5747256 | 0.80 | FGFR1 (0.48) | TYK2GPR6FGFR1SRCEGFR | |
| SCHEMBL5749479 | 0.80 | CYP46A1 (0.37) | EGFRKDRROCK2 | |
| SCHEMBL5777109 | 0.79 | GAA (0.39) | ROCK2 | |
| SCHEMBL5866958 | 0.79 | FGFR1 (0.36) | FGFR1SRCKDRROCK2 | |
| SCHEMBL5751077 | 0.78 | PDGFRB (0.40) | GPR6FGFR1SRCEGFRROCK2 | |
| SCHEMBL5749199 | 0.78 | FGFR1 (0.62) | FGFR1SRCEGFRFGFR2FGFR4 | |
| SCHEMBL5866821 | 0.78 | FGFR1 (0.43) | TYK2FGFR1SRCEGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | claimed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | claimed |
| EP-1372648-A4 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | claimed |
| EP-1372648-A2 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002060382-A2 | NOVEL COMPOUNDS AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | claimed |
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1372648-A4 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| EP-1372648-A2 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002060382-A2 | NOVEL COMPOUNDS AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048888-A1 | Novel compounds and uses thereof | TEK, TIE1, KDR | TYK2 1621/4885GPR6 537/4885FGFR1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.